Clinical Trials Logo

Recurrent or Refractory T/NK-cell Malignancies clinical trials

View clinical trials related to Recurrent or Refractory T/NK-cell Malignancies.

Filter by:
  • None
  • Page 1

NCT ID: NCT00823355 Completed - Clinical trials for Recurrent or Refractory T/NK-cell Malignancies

Oral Forodesine Hydrochloride (BCX-1777) in Patients With Recurrent or Refractory T/NK-cell Malignancies

Start date: January 2009
Phase: Phase 1
Study type: Interventional

Primary objectives are to evaluate the safety profile and tolerability of oral BCX1777 in each cohort of patients with recurrent or refractory T/NK-cell malignancies and to evaluate pharmacokinetics (PK) of oral BCX1777.